ArticleThe American journal of medicine2013
Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease.
Article in The American journal of medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Efficacy of medication therapy for patients with chronic kidney disease and heart failure with preserved ejection fraction: a systematic review and meta-analysis.International urology and nephrology · 2022Pooled it
- Digoxin use and lower risk of 30-day all-cause readmission in older patients with heart failure and reduced ejection fraction receiving β-blockers.Clinical cardiology · 2018Trial
- Rate-control versus rhythm-control strategies and outcomes in septuagenarians with atrial fibrillation.The American journal of medicine · 2013Trial
- Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial.European heart journal · 2013Trial
- Outcomes of KDIGO-Defined CKD in U.S. Veterans With HFpEF, HFmrEF, and HFrEF.JACC. Heart failure · 2025Article
- Diastolic Dysfunction and Renal Disease: Analysis, Mechanisms, and Different Perspectives.Cureus · 2025Review
- Inflammation Links Cardiac Injury and Renal Dysfunction: A Cardiovascular Magnetic Resonance Study.Reviews in cardiovascular medicine · 2024Article
- Renin-Angiotensin Inhibition and Outcomes in HFrEF and Advanced Kidney Disease.The American journal of medicine · 2023Article
- Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension.The American journal of medicine · 2021Article
- Length of stay and readmission in older adults hospitalized for heart failure.Archives of medical science : AMS · 2021Article
- Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.The American journal of medicine · 2020Article
- Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction.Journal of the American College of Cardiology · 2019Article
- Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction.The American journal of medicine · 2019Article
- Therapeutic Approach to Patients with Heart Failure with Reduced Ejection Fraction and End-stage Renal Disease.Current cardiology reviews · 2018Review
- Digoxin and 30-Day All-Cause Readmission in Long-Term Care Residents Hospitalized for Heart Failure.Journal of the American Medical Directors Association · 2017Article
- Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone.International journal of cardiology · 2017Article
- Association of 30-Day All-Cause Readmission with Long-Term Outcomes in Hospitalized Older Medicare Beneficiaries with Heart Failure.The American journal of medicine · 2016Article
- Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure.The American journal of medicine · 2015Article
- Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart Failure.Circulation. Heart failure · 2015Article
- Orthostatic hypotension and incident heart failure in community-dwelling older adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundThe role of renin-angiotensin inhibition in older patients with diastolic heart failure and chronic kidney disease remains unclear.
methodsOf the 1340 patients (age ≥65 years) with diastolic heart failure (ejection fraction ≥45%) and chronic kidney disease (estimated glomerular filtration rate <60 mL/min/1.73 m(2)), 717 received angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Propensity scores for the use of these drugs, estimated for each of the 1340 patients, were used to assemble a cohort of 421 pairs of patients, receiving and not receiving these drugs, who were balanced on 56 baseline characteristics.
resultsDuring more than 8 years of follow-up, all-cause mortality occurred in 63% and 69% of matched patients with chronic kidney disease receiving and not receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, respectively (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.70-0.97; P = .021). There was no association with heart failure hospitalization (HR, 0.98; 95% CI, 0.82-1.18; P = .816). Similar mortality reduction (HR, 0.81; 95% CI, 0.66-0.995; P = .045) occurred in a subgroup of matched patients with an estimated glomerular filtration rate less than 45 mL/min/1.73 m(2). Among 207 pairs of propensity-matched patients without chronic kidney disease, the use of these drugs was not associated with mortality (HR, 1.03; 95% CI, 0.80-1.33; P = .826) or heart failure hospitalization (HR, 0.99; 95% CI, 0.76-1.30; P = .946).
conclusionsA discharge prescription for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was associated with a significant reduction in all-cause mortality in older patients with diastolic heart failure and chronic kidney disease, including those with more advanced chronic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.